Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Accelerated Approval: Potential Sources Of Confirmatory Evidence Weighed At Tofersen Review

Mar 24 2023

• By Sue Sutter

Eggs in nest — Biogen has proposed several sources of confirmatory and supportive evidence for tofersen's clinical benefit. • Source: Shutterstock

Related Content

Accelerated Approval Reforms Give US FDA More Power And Flexibility – With Some Gaps

Dec 21 2022

A Greater Power: US FDA May Become More Insistent On Timing Of Accelerated Approval Confirmatory Trials

Jan 26 2023

Accelerated Approval Is US FDA Panel’s Preferred Path For Biogen/Ionis’s Tofersen In ALS

Mar 23 2023

Biogen/Ionis’ Tofersen: US FDA Considering Both Accelerated And Regular Approval In ALS

Mar 20 2023

US FDA Neuroscience Office Director Billy Dunn Departs As Agency Faces New Review Challenges

Feb 27 2023

Related Companies

Biogen, Inc.

Ionis Pharmaceuticals, Inc.

Neumora Therapeutics, Inc.

Additional Topics

United States Advisory Committees Review Pathway Real-World Evidence Drug Review Rare Diseases Regulation Neurology BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window